Although these data suggest an inhibitory role for IGFBP-3 in bone metabolism, other in vivo data (119) and cross-sectional studies in a cohort of female patients with postmenopausal osteoporosis suggest an anabolic role for IGFBP-3 in maintaining bone density (120). Here, IGFBP3 is linked to postmenopausal osteoporosis.